Illinois Municipal Retirement Fund boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 6.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 369,834 shares of the biopharmaceutical company’s stock after acquiring an additional 22,969 shares during the quarter. Gilead Sciences makes up approximately 0.6% of Illinois Municipal Retirement Fund’s holdings, making the stock its 20th biggest holding. Illinois Municipal Retirement Fund’s holdings in Gilead Sciences were worth $45,393,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of GILD. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in Gilead Sciences by 52.1% in the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock valued at $8,713,000 after buying an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. increased its stake in shares of Gilead Sciences by 249.1% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after purchasing an additional 7,168 shares during the last quarter. NewEdge Wealth LLC raised its stake in shares of Gilead Sciences by 2.9% in the third quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock valued at $75,962,000 after buying an additional 17,284 shares during the period. Nordea Investment Management AB lifted its holdings in Gilead Sciences by 16.5% during the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after purchasing an additional 726,101 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Gilead Sciences by 4.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 161,155 shares of the biopharmaceutical company’s stock valued at $17,888,000 after buying an additional 6,680 shares in the last quarter. 83.67% of the stock is owned by institutional investors.
More Gilead Sciences News
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead and Merck reported positive Phase 3 results for a once-weekly HIV regimen using islatravir and lenacapavir, a potential advance that could strengthen Gilead’s already important HIV franchise and support long-term revenue growth. Article Title
- Positive Sentiment: Analysts and recent commentary pointed to momentum in Gilead’s HIV portfolio, including strength in Biktarvy and Descovy, as well as improving expectations for Yeztugo and other late-stage pipeline assets. Article Title
- Positive Sentiment: Gilead said topline Phase 3 IDEAL study results for Livdelzi in primary biliary cholangitis showed significantly more patients reached key treatment goals, which could broaden the company’s pipeline and add another growth driver. Article Title
- Neutral Sentiment: Gilead presented at the Goldman Sachs Global Healthcare Conference, which likely reinforced management’s pipeline and growth narrative but did not appear to include a major new catalyst. Article Title
- Negative Sentiment: Gilead and Merck also ended a Phase 3 lung cancer study after Trodelvy plus KEYTRUDA failed to deliver a statistically significant improvement, renewing concern around Gilead’s oncology strategy. Article Title
- Negative Sentiment: Biopharma coverage noted that the Trodelvy setback creates risk for one of Gilead’s key cancer programs, even as HIV progress remains the bigger driver for the stock. Article Title
Analyst Upgrades and Downgrades
Read Our Latest Report on Gilead Sciences
Gilead Sciences Stock Performance
Shares of NASDAQ GILD opened at $121.48 on Thursday. The firm’s fifty day moving average is $133.73 and its two-hundred day moving average is $134.34. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The company has a market cap of $150.83 billion, a P/E ratio of 16.55 and a beta of 0.31.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the business earned $1.81 EPS. The business’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.
Insider Transactions at Gilead Sciences
In other news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares in the company, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares of the company’s stock, valued at $81,185,357.82. This represents a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 68,000 shares of company stock valued at $9,047,570. Corporate insiders own 0.30% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Stories
- Five stocks we like better than Gilead Sciences
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
